EP Patent

EP3048104A1 — Amorphous and crystalline forms of idelalisib and process for forming the same

Assigned to Sandoz AG · Expires 2016-07-27 · 10y expired

What this patent protects

The present invention concerns pure and stable amorphous idelalisib, crystalline solvates of idelalisib and a process for the formation of pure and stable amorphous idelalisib using the crystalline solvates of idelalisib.

USPTO Abstract

The present invention concerns pure and stable amorphous idelalisib, crystalline solvates of idelalisib and a process for the formation of pure and stable amorphous idelalisib using the crystalline solvates of idelalisib.

Drugs covered by this patent

Patent Metadata

Patent number: EP3048104A1
Jurisdiction: EP
Classification: —
Expires: 2016-07-27
Drug substance claim: No
Drug product claim: No
Assignee: Sandoz AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.